{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"14"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"21"}],"units":"Participants"}],"description":"-Incidence and severity of acute GVHD will be assessed based on the Seattle criteria. Attempts should be made to confirm the diagnosis pathologically by biopsy of target organ(s).","groups":[{"description":"Conditioning Regimens\n\n* fludarabine and busulfan +/- thymoglobulin\n* fractionated total body irradiation and cyclophosphamide\n* busulfan and cyclophosphamide\n* single dose total body irradiation and cyclophosphamide\n\nDay -2 = GvHD prophylaxis\n\nDay 0 or +1 = PBSC transplant\n\nDay +7 until neutrophil engraftment = G-CSF 5 ug/kg/day","id":"OG000","title":"Arm 2 - Recipient"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"3 of the recipients received cells mobilized by 10 mcg/kg of GM-CSF and the 11 recipients received stem cells from donors mobilized with the decreased dose of 5 mcg/kg of GM-CSF.","reportingStatus":"POSTED","timeFrame":"Up through Day 100","title":"Rate of Acute Graft vs. Host Disease (GvHD) (Recipient Only)","type":"SECONDARY","unitOfMeasure":"Participants"}